title: [Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kawada
authors.forename: Naomichi
authors.initials: N
authors.lastname: Arima
mesh_terms: D001897:Boronic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D015195:Drug Design; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D000077269:Lenalidomide; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D009842:Oligopeptides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010954:Plasmacytoma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D007155:Immunologic Factors; D009842:Oligopeptides; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; C524865:carfilzomib; C467566:pomalidomide; D000077269:Lenalidomide